# Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)

> **NCT01423825** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 27 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** Sub C gp140 Vaccine
- **BIOLOGICAL:** MF59C.1 Adjuvant
- **OTHER:** Sodium chloride

## Key facts

- **NCT ID:** NCT01423825
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2021-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01423825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01423825, "Evaluating the Safety and Immune Response to an HIV Vaccine Boost Following the Administration of Two HIV Vaccines, in HIV-Uninfected, Healthy Adults (Study Extension to HVTN 073/SAAVI 102)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01423825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*